Adaptimmune Therapeutics PLC — Director's Dealing 2018

Jun 26, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2018-06-22

Reporting Person: Duncan Barbara Gayle (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-22	Option to purchase Ordinary Shares	$2.18	A	158233	Acquired	2028-06-22	Ordinary Shares (158233)	Direct

Footnotes

F1: The exercise price was converted from GBP1.65 based on an exchange rate of $U.S. 1.3250 to GBP1.00. The actual exercise price will be the pounds sterling amount.